Barely Significant

Excerpts

5,102 sentences · 1 filter applied

Patients with CSF flow at the CCJ before surgery (0–2 points at CSF flow score, Table 1 ) tend to have a higher probability (OR = 4.75, IC 95% 0.95–23.85, at the limit of significance) of post-surgical improvement than patients with absent CSF flow at the CCJ (3 points at the CSF flow score, Table 1 ).
As far as the subgroup of naive patients with HCC is concerned, the overall proportion of patients deemed eligible for atezolizumab plus bevacizumab was 7.1%, ranging from 5.3% to 5.4% (2008–2014) up to 10.7% (2019), with a median eligibility rate for the novel therapy in this group of patients of 7.5%, and with an increasing trend observed in the most recent years ( Figure 3 A).
With regard to patients with HCC recurrence after surgery or locoregional treatment, after excluding those not eligible for the treatment with atezolizumab plus bevacizumab as per the study inclusion and exclusion criteria, the overall eligibility rate to this ICI-based therapy was 36.3%, with a median eligibility rate across the whole period of 36.5% (range, 28.9% to 44.4%), with a decreasing trend observed in the most recent years ( Figure 3 B).